Skip to main content
. 2023 Nov 23;16(12):2458–2466. doi: 10.1111/cts.13677

FIGURE 2.

FIGURE 2

Key clinical trials of vericiguat throughout phases of development. HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; PD, pharmacodynamics; PK, pharmacokinetics. aA study to assess vericiguat as victim of PK drug–drug interactions. bA study to assess vericiguat as perpetrator of PK drug–drug interactions.